Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.

Cancer research - 1 Sept 2017

Richer Amanda L, Cala Jacqueline M, O'Brien Kelley, Carson Vashti M, Inge Landon J, Whitsett Timothy G

Abstract excerpt

G1-S checkpoint loss contributes to carcinogenesis and increases reliance upon the G2-M checkpoint for adaptation to stress and DNA repair, making G2-M checkpoint inhibition a target for novel therapeutic development. AZD1775, an inhibitor against the critical G2-M checkpoint protein WEE1, is currently in clinical trials across a number of tumor types. AZD1775 and DNA-damaging agents have displayed favorable...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to AMP-Activated Protein Kinases
Share to Cell Cycle Checkpoints

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Evaluation, Preclinical

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins p21(ras)

Share to Pyrazoles

Share to Pyrimidines

Share to Pyrimidinones

Source

Identifiers

PMID: 28652249
DOI: 10.1158/0008-5472.CAN-16-3565

Genes

KRAS
WEE1
ATM
STK11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.PMID 28652249Read ↗

Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancerSemantic proximity Read ↗

GCN2 is a determinant of the response to WEE1 kinase inhibition in small-cell lung cancerSemantic proximity Read ↗

Development of Potent Pyrazolopyrimidinone‐Based WEE1 Inhibitors with Limited Single‐Agent Cytotoxicity for Cancer TherapySemantic proximity Read ↗

Wee1 Rather Than Plk1 Is Inhibited by AZD1775 at Therapeutically Relevant ConcentrationsSemantic proximity Read ↗

Molecular Pathways: Targeting the Protein Kinase Wee1 in CancerSemantic proximity Read ↗

MK1775, a Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity against Sarcoma CellsSemantic proximity Read ↗

PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors.Semantic proximity Read ↗

LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition.Semantic proximity Read ↗

KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancerSemantic proximity Read ↗

CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibitionSemantic proximity Read ↗

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.Semantic proximity Read ↗

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agentsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.